TALMAPIMOD
Talmapimod is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against mitogen-activated protein kinase 11 and mitogen-activated protein kinase 14.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
6 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | 2 | — | — | — | 3 |
| Arthritis | D001168 | HP_0001369 | M05-M14 | 1 | 2 | — | — | — | 3 |
| Multiple myeloma | D009101 | — | C90.0 | — | 2 | — | — | — | 2 |
| Plasma cell neoplasms | D054219 | — | — | — | 2 | — | — | — | 2 |
| Myelodysplastic syndromes | D009190 | — | D46 | — | 1 | — | — | — | 1 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | 1 | — | — | — | 1 |
| Preleukemia | D011289 | — | — | — | 1 | — | — | — | 1 |
| Bone marrow diseases | D001855 | — | — | — | 1 | — | — | — | 1 |
| Syndrome | D013577 | — | — | — | 1 | — | — | — | 1 |
| Bone marrow neoplasms | D019046 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TALMAPIMOD |
| INN | talmapimod |
| Description | Talmapimod is an indolecarboxamide obtained by formal condensation of the carboxy group of 6-chloro-3-[(dimethylamino)(oxo)acetyl]-1-methylindole-5-carboxylic acid with the secondary amino group of (2S,5R)-1-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazine. It is a potent inhibitor of MAPK and exhibits anti-cancer properties. It has a role as an EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor, an apoptosis inducer and an antineoplastic agent. It is a N-acylpiperazine, a N-alkylpiperazine, an aromatic amide, a member of monofluorobenzenes, a chloroindole, an indolecarboxamide, a dicarboxylic acid diamide and an aromatic ketone. |
| Classification | Small molecule |
| Drug class | immunomodulators: mitogen-activated protein (MAP) kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H]1CN(C(=O)c2cc3c(C(=O)C(=O)N(C)C)cn(C)c3cc2Cl)[C@H](C)CN1Cc1ccc(F)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 309913-83-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL514201 |
| ChEBI ID | 90683 |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | B1E00KQ6NT (ChemIDplus, GSRS) |
Target
Agency Approved
MAPK11
MAPK11
MAPK14
MAPK14
Organism
Homo sapiens
Gene name
MAPK11
Gene synonyms
PRKM11, SAPK2, SAPK2B
NCBI Gene ID
Protein name
mitogen-activated protein kinase 11
Protein synonyms
MAP kinase 11, MAP kinase p38 beta, Mitogen-activated protein kinase p38 beta, mitogen-activated protein kinase p38-2, p38-2, p38b, SAPK2b, Stress-activated protein kinase 2b, stress-activated protein kinase-2, stress-activated protein kinase-2b
Uniprot ID
Mouse ortholog
Mapk11 (19094)
mitogen-activated protein kinase 11 (Q9WUI1)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 186 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
57 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use